Drug
Golodirsen Vyondys 53
Golodirsen Vyondys 53: highest development phase Post-Market, developed by Sarepta Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] NCT04708314 | Post-Market | Duchenne Muscular Dystrophy |
Latest
No recent events.
Follow Golodirsen Vyondys 53 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.